JP Morgan Cazenove Reiterates Hikma Pharmaceuticals PLC - Depositary Receipt (HKMPY) Overweight Recommendation

JP Morgan Cazenove reiterated an "Overweight" recommendation for Hikma Pharmaceuticals PLC (OTCPK:HKMPY), setting an average one-year price target of $66.69, which suggests a 33.11% upside from its current $50.10. This positive analyst stance is noted despite a projected 10.45% decrease in annual revenue to $2,880MM and a non-GAAP EPS of $2.12. Institutional activity shows a slight decrease in total shares owned by institutions, down 11.43% to 16K, even as the average portfolio weight among holding funds increased by 4.90%.

Analysis

JP Morgan Cazenove reiterated an "Overweight" recommendation for Hikma Pharmaceuticals PLC (OTCPK:HKMPY) on November 7, 2025. This positive stance is supported by an average one-year price target of $66.69, suggesting a substantial 33.11% upside from the current $50.10 closing price. The target range spans from $53.42 to $80.28, indicating a broad spectrum of potential outcomes.

Despite the bullish analyst rating, Hikma Pharmaceuticals faces a projected annual revenue decrease of 10.45% to $2,880 million. The company is also projected to achieve a non-GAAP EPS of $2.12. This juxtaposition of a strong analyst recommendation against declining revenue projections warrants closer examination, potentially implying the analyst sees value beyond top-line growth or expects other operational efficiencies.

Institutional investor activity presents a mixed signal, with total shares owned by institutions decreasing by 11.43% to 16,000 shares over the last three months. Specifically, PENN MUTUAL AM 1847 INCOME FUND I (PMEFX), the only fund mentioned, reduced its holdings by 12.90% from 18,000 to 16,000 shares. While the average portfolio weight of funds dedicated to HKMPY reportedly increased by 4.90%, the overall trend in share ownership among institutions appears to be negative.

Key Decisions for Investors

• Investors should investigate the underlying drivers of JP Morgan's "Overweight" recommendation, given the projected 10.45% annual revenue decrease.
• Closely monitor upcoming institutional ownership reports for HKMPY, as recent data indicates a net decrease in total shares held by institutions despite an increase in average portfolio weight among existing holders.
• Assess the company's fundamental outlook and valuation metrics, such as the $2.12 non-GAAP EPS, to determine if the 33.11% price target upside is justified by operational performance or market re-rating.